Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CeloNova BioSciences, Inc.
San Antonio, Texas, United Statescelonova.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The COBRA PzF stent met pre-specified performance goals for both the primary endpoint of target vessel failure and the secondary endpoint of angiographic late lumen loss at 9-months post-intervention in the PzF SHIELD clinical trial[7]. The company also received FDA approval for an IDE clinical trial for Oncozene embolic microspheres loaded with doxorubicin for hepatocellular carcinoma treatment[6].
- Therapeutic areas
- Women's HealthOncologyCardiovascular
- Modalities
- Medical device coatingsDrug-eluting microspheresCoronary stents
- Industry
- Surgical Medical Devices
Beyond the preview
Go deeper on CeloNova BioSciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CeloNova BioSciences, Inc..